Posts Tagged: Pharma & Chemical


Biotech and Pharma Update: News for December 2013

What follows below is a review of some of the biotech and pharma news stories that caught my attention during the month of December 2013. Fitch Puts Negative …
By Gene Quinn
6 years ago 0

Protecting Data Exclusivity, Protecting the Future of Medicine

Traditionally, “small molecule” drugs are patent protected for a twenty-year term. Biologic medicines, however, are more difficult to comprehensively protect with patents due to their size, complexity, …

Pharma & Biotech News for September 2013

Mark Lemley's Firm Files DJ Against Myriad in Northern California ----- Promise Not to Infringe Insufficient in ANDA Litigation ----- Licensing Deals Stall in Pharmaceutical Sector in …
By Gene Quinn
7 years ago 0

Compulsory Licenses and “Statements of Working” in India

As many following India IP issues are well-aware, in 2012 India issued the 1st compulsory license (CL) to Natco for Bayer’s anti-cancer drug Nexavar. The granting of …
By Michael Lin
7 years ago 1

Patent Law 2.0: Not the Answer the Developing World Needs

In a recent article in the New England Journal of Medicine, Amy Kapczynski argues that the Supreme Court of India’s strict interpretation of the country’s …

In re Effexor XR Antitrust Litigation: FTC Amicus Argues for No-Authorized-Generic in Patent Settlements

The Federal Trade Commission has asked the U.S. District Court for the District of New Jersey to accept an amicus brief that addresses the application of …

Pharma Update July 2013: FDA, Preemption & SCOTUS

The FDA is following through on plans to issue a proposed rule to revise regulations to allow generic drugmakers to update labeling. The rule would update current …
By Ed Silverman
7 years ago 0

Pharma Scandals: Bribery, Insider Trading and Paula Deen

The summer may be in full swing, but the torrent pace of news and interesting developments has not subsided at all. Hot days simply yield hot stories. …
By Ed Silverman
7 years ago 0

Why SCOTUS Myriad Ruling Overrules Chakrabarty

The Supreme Court quite directly contradicts the reasoning of Chakrabarty in Myriad. Thomas explains that it is a fact that isolated DNA is nonnaturally occurring, but still …
By Gene Quinn
7 years ago 30

FDA Approves New Labeling for Merck Blockbuster HIV Drug ISENTRESS

This newly approved, updated prescribing information for ISENTERSS now includes 240-week results from the STARTMRK study, the double-blind Phase III study that evaluated integrase inhibitor in previously …
By Gene Quinn
7 years ago 0

Pharma Law and Business Roundup: June 2013

After years of debate and controversy, the US Supreme Court ruled that drugmakers can face lawsuits over so-called pay-to-delay patent settlements, but that such deals should not …
By Ed Silverman
7 years ago 0

Global IP Reaction to India’s Rejection of the Novartis Drug Patent

India’s booming $26 billion generic drug industry and public health sector rejoiced over the Indian Supreme Court’s recent decision to reject a patent filed by the …
By Lisa Kilday
7 years ago 1

Are Pharmaceutical Patents A Barrier to Access to Medicines? The Importance Economic Development and Growth

Critics argue that pharmaceutical patents are a barrier to wide-reaching access to medicines, especially for vulnerable populations in the developing world. They cast their argument in the …

Bio-Pharma at the U.S. Supreme Court

Since my last article here on IPWatchdog.com, the pharmaceutical industry has been simply overflowing with interesting developments, including the US Supreme Court hearing arguments concerning three …
By Ed Silverman
7 years ago 1

Pharma Law and Business Roundup for March 2013

In response to the scandal over a fungal meningitis outbreak, the FDA has begun a crackdown on compounding pharmacies and targeting about 30 ‘high risk’ operations in nearly …
By Ed Silverman
7 years ago 0